A Phase 2 interventional study of Cabozantinib and Pembrolizumab in Pancreatic Cancer, sponsored by Joseph Kim. Completed at 1 site in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-11-19.
Sponsored by Joseph Kim · Phase 2, Interventional, and Treatment
This study aims to evaluate cabozantinib and pembrolizumab for the treatment of metastatic pancreatic adenocarcinoma.
3,235 studies on the registry are indexed under Pancreatic Neoplasms; 898 are open to participants now.
This study's enrollment of 21 is below the median of 46 across 2,424 interventional studies indexed under Pancreatic Neoplasms.
Browse Pancreatic Neoplasms studies →Joseph Kim is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: Cabozantinib · Drug: Pembrolizumab
Cabozantinib (XL184) is a potent inhibitor of multiple receptor tyrosine kinases (RTKs) known to play important roles in tumor cell proliferation and/or tumor neovascularization.
Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD-1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2).
Progression-free Survival
Progress-free survival in participants, defined as the time from the start of treatment until the first documentation of disease progression or death due to any cause, whichever comes first.
Time frame: 1 year
Number of Participants With Response to Therapy
The proportion of participants with overall response to therapy via imaging; Overall Response Rate (%) = (Number of patients achieving Complete responses + Number of patients achieving partial responses / Total Number of patients) × 100
Time frame: 1 year
Number of Participants With Complete Response
The proportion of participants with a complete response to therapy
Time frame: 1 year
Number of Participants With Partial Response
The proportion of participants with a partial response to therapy
Time frame: 1 year
Overall Participant Survival Rate
Overall survival rate participants
Time frame: 1 year
| Milestone | Cabozantinib and pembrolizumab |
|---|---|
| Started | 21 |
| Completed | 2 |
| Not completed | 19 |
| Withdrew: Death | 19 |
Progress-free survival in participants, defined as the time from the start of treatment until the first documentation of disease progression or death due to any cause, whichever comes first.
| Participants | Cabozantinib and pembrolizumab |
|---|---|
| Progression-free Survival | 2 |
The proportion of participants with overall response to therapy via imaging; Overall Response Rate (%) = (Number of patients achieving Complete responses + Number of patients achieving partial responses / Total Number of patients) × 100
| Participants | Cabozantinib and pembrolizumab |
|---|---|
| Number of Participants With Response to Therapy | 1 |
The proportion of participants with a complete response to therapy
| Participants | Cabozantinib and pembrolizumab |
|---|---|
| Number of Participants With Complete Response | 0 |
The proportion of participants with a partial response to therapy
| Participants | Cabozantinib and pembrolizumab |
|---|---|
| Number of Participants With Partial Response | 1 |
Overall survival rate participants
| Participants | Cabozantinib and pembrolizumab |
|---|---|
| Overall Participant Survival Rate | 2 |
Collected over 1 year. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cabozantinib and pembrolizumab | 19/21 (90.5%) | 13/21 (61.9%) | 20/21 (95.2%) |
| Event | Cabozantinib and pembrolizumab |
|---|---|
| NauseaGastrointestinal disorders | 3/21 |
| Alkaline phosphatase increasedInvestigations | 3/21 |
| Acute kidney injuryRenal and urinary disorders | 3/21 |
| Abdominal PainGastrointestinal disorders | 2/21 |
| DiarrheaGastrointestinal disorders | 2/21 |
| Disease ProgressionGeneral disorders | 2/21 |
| SepsisInfections and infestations | 2/21 |
| Blood bilirubin increasedInvestigations | 2/21 |
| DehydrationMetabolism and nutrition disorders | 2/21 |
| HypokalemiaMetabolism and nutrition disorders | 2/21 |
| Event | Cabozantinib and pembrolizumab |
|---|---|
| FatigueGeneral disorders | 14/21 |
| Metabolism and nutrition disordersInvestigations | 14/21 |
| DiarrheaGastrointestinal disorders | 11/21 |
| NauseaGastrointestinal disorders | 11/21 |
| HypocalcemiaInvestigations | 11/21 |
| Aspartate aminotransferase increasedInvestigations | 10/21 |
| AnorexiaInvestigations | 10/21 |
| Alanine aminotransferase increasedInvestigations | 9/21 |
| HypoalbuminemiaInvestigations | 8/21 |
| HypertensionVascular disorders | 8/21 |
| Age, Continuous(years) | Cabozantinib and Pembrolizumab |
|---|---|
| Mean | 66 ± 7.19 |
| Sex: Female, Male(Participants) | Cabozantinib and Pembrolizumab |
|---|---|
| Female | 11 |
| Male | 10 |
| Ethnicity (NIH/OMB)(Participants) | Cabozantinib and Pembrolizumab |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 20 |
| Unknown or Not Reported | 1 |
| Race (NIH/OMB)(Participants) | Cabozantinib and Pembrolizumab |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 2 |
| White | 18 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
| Region of Enrollment(participants) | Cabozantinib and Pembrolizumab |
|---|---|
| United States | 21 |
Documents are hosted by the registry — open the source record to download them.
Plan to share: No
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Joseph Kim